Even women with typically regular periods can sometimes experience minor hormonal fluctuations that lead to a late period
No Fast Track designation, Breakthrough Therapy designation, or other FDA expedited review pathway has been publicly announced for retatrutide as of February 2026
This triple-pathway mechanism distinguishes retatrutide from existing obesity drugs such as semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro/Zepbound), which only activate one or two pathways
Use the Peptide Unit Converter to verify conversions
In a study involving streptozotocin (STZ)-induced diabetic rats, treatment with exenatide did not significantly affect blood sugar levels, insulin levels, or the thermal response latencies of the paws
These findings have strongly supported the hypothesis that the use of GLP-1RAs might be a novel effective treatment for PD